Oct 2025 Opioid Use Disorder: Evaluating Risk of Return to Use
Supporting patients with opioid use disorder (OUD) requires ongoing vigilance, as the risk of return to use remains a critical...
In Practice: Clinical Insights
Aug 2025 2025 Mid-Year Update on Novel Psychoactive Substances (NPS) Trends
The goal of this clinical update is to review the prevalence of NPS detected at Aegis and trends in detection...
Jun 2025 New Additions to the Aegis Behavioral Health Testing Menu
Benztropine & Trihexyphenidyl Pharmacology: Benztropine and trihexyphenidyl are anticholinergic drugs that block muscarinic acetylcholine...
Apr 2025 Prevalent Adulterants Found in the Illicit Drug Supply
Adulterants are unreported substances added to a product, often to reduce production costs, enhance the products effects, and may increase...
Feb 2025 Novel Psychoactive Substances 2024: A Year in Review
The focus of this clinical update is to evaluate changes observed in the prevalence of NPS detected at Aegis in...
Nov 2024 Ketamine: Considerations in Clinical Practice
Ketamine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. It is FDA approved for the induction and maintenance of anesthesia.1 When used...
